Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkins Lymphoma (NHL) After Allogeneic Stem Cell Transplantation.

Trial Profile

Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkins Lymphoma (NHL) After Allogeneic Stem Cell Transplantation.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs FBTA 05 (Primary) ; T cell replacement therapy
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
    • 25 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016.
    • 02 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top